Advanced Tissue Sciences begins trials for periodontal treatment, heart tissue patch.Advanced Tissue Sciences (ATS), La Jolla, CA announced it has begun 2 trials - one in tissue used in periodontal surgery, and a second with a tissue-engineered product to treat damaged heart tissue. In early July the company received approval from the US Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to begin a pivotal clinical trial for the use of its core technology, a human fibroblast-derived dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. substitute, as a substitute for a soft tissue graft during periodontal surgery. The FDA has already granted ATS approval to use the product in the treatment of diabetic food ulcers under the name of Dermagraft. The procedure consists of taking a donor graft from the patient's own palatal pal·a·tal adj. Palatine. palatal (pal´  t tissue, placing it over the exposed root and
covered by a flap of gingival gingival (jin´j v tissue which is designed to prevent
further recession and maintain the health of the tooth. Up to 50
patients are expected to participate in the trial. ATS says the average
improvement in gingival recession with the product will be compared to
the improvement achieved with the patient's own tissue.
ATS also has initiated a pivotal preclinical trial for Anginera, a tissue-engineered epicardial epicardial pertaining to the visceral pericardium (epicardium) or to the epicardia. epicardial receptors receptors in the left ventricle adapted to respond to stretch and chemical stimulants. patch. The company says Anginera has previously been shown to stimulate the growth of new blood vessels and improve function of damaged heart tissue in mice. The trial will examine the safety of the product when applied to ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic hearts in large animals. The animal studies are required by the FDA prior to beginning human clinical trials. Contact: Julie Reynolds - (858) 713-7802, Web site - www.advancedtissue.com. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion